• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Zanidatamab Plus Chemotherapy Shows Promising Anti-Tumor Activity in Treatment of HER2-Mutated Breast Cancer

by MM360 Staff | May 21, 2025 | Myeloma News

Source: Pharmacy Times articles The data were presented at the ESMO Breast Cancer 2025 Annual Meeting. Read More

Denosumab With Ovarian Function Suppression and Aromatase Inhibitor Therapy in ER-Positive, Early-Stage Breast Cancer

by MM360 Staff | May 21, 2025 | Myeloma News

Source: Pharmacy Times articles In premenopausal women, denosumab significantly prevented bone loss and microarchitectural deterioration. Read More

Study Links MUC1-C to Estrogen Receptor Expression and Endocrine Resistance in HR+/HER2– Breast Cancer

by MM360 Staff | May 21, 2025 | Myeloma News

Source: Pharmacy Times articles Studies suggest that prolonged activation of MUC1-C encourages disease progression. Read More

Study Finds Increased Risk of CVD Among Women With History of Infertilty

by MM360 Staff | May 21, 2025 | Myeloma News

Source: Pharmacy Times articles The risk of cardiovascular disease (CVD) was higher among those who were exposed to assisted reproductive technology. Read More

Zuranolone in Postpartum Depression

by MM360 Staff | May 21, 2025 | Myeloma News

Source: Pharmacy Times articles The treatment could hold significant potential for major depressive disorder Read More

Anti-Diabetic Drug Could Offer New Treatment for Prostate Cancer

by MM360 Staff | May 20, 2025 | Myeloma News

Source: Pharmacy Times articles Research reveals pioglitazone, a diabetes drug, may slow prostate cancer progression, offering new hope for patients with both conditions. Read More
« Older Entries
Next Entries »

Recent Content

  • Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
  • Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
  • Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
  • (no title)
  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • (no title)
  • Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
  • (no title)
  • Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT